LONDON (Reuters) – European and British regulators said on Wednesday they found a possible link between AstraZeneca’s vaccine and a very rare case of blood clots. But it reaffirms the importance of protecting people from COVID-19.
A group of British government advisers said the vaccine should not be given to people under the age of 30 if possible, although officials said this was a “With the utmost care, instead of because we have a serious safety concern.”;
At one time, dozens of countries suspended the use of the vaccine, which has already been given to tens of millions of people in Europe. But most have resumed their work and some, including France, the Netherlands and Germany, have set a minimum age.
Now, the growing infection caused by a growing infectious pattern is threatening the hospitals of many EU countries, where vaccination is much delayed than the UK and the United States and forcing France and others to turn around. Socio-economic blockade again
The European Medicines Agency (EMA) received a report of 169 cases of a rare cerebral blood clot by early April after 34 million doses in the European Economic Area, according to Sabine Straus, chair of the EMA Safety Committee. 27 EU countries including Iceland, Norway and Liechtenstein
By comparison, four out of 10,000 women will get a blood clot from taking the contraceptive pill.
In a statement, the EMA said it warned healthcare professionals and clients of “the possibility of an extremely rare blood clot with low platelet aggregation occurring within 2 weeks of vaccination”.
No new approach
“Until now, most cases were reported in women under 60 within 2 weeks of vaccination,” it added, but no new guidelines were issued.
Professor Frederic Adnet, head of emergency services at Avicenne Hospital in Bobigny, France, said the order would affect the French acquisition, where there is a high level of suspicion about the vaccine.
“EMA’s communications today will undoubtedly influence AstraZeneca’s confidence in the vaccine,” he said.
The EU’s health ministers started their meeting shortly after the EMA statement.
AstraZeneca shots sell for just a few dollars per drug. So far it is the cheapest and highest dose vaccine, and there are no severe refrigeration requirements for the other COVID-19 vaccines.
After extensive use in the UK and mainland Europe, it has been named a mainstay of vaccination programs in most developing countries.
The World Health Organization’s Advisory Vaccine Safety Committee said a causal link to blood clots with low platelet aggregation. “Considered possible. But not confirmed “
Experts say that although a causal link has been proven. But the risk to the general population of getting a serious clot is very small compared to the risk of COVID-19 infection that could cause a similar blockage or from many other more widespread uses. Like birth control pills
“The risk of death from COVID is greater than the risk of death from these rare side effects,” said EMA Executive Director Emer Cooke.
The benefits at risk
AstraZeneca shares, however, were down 1.2 percent at a two-week low.
But the shooting has been faced with questions since late last year when the drugmaker and the University of Oxford published trial data with two different efficacy readings as a result of errors in use. drug
Last month, the company published early results of a late-stage U.S. clinical trial showing that the shooting was 79 percent effective, but then struggled to disclose more information after blaming U.S. health officials. Which said the information is out of date
Britain’s chief drug regulator, June Raine, said the benefits outweigh most people’s risks. But there is more balance for younger people, who, on average, their coronavirus risk is lower.
Wei Shen Lim, Chair of the UK COVID-19 Joint Advisory Committee on Vaccines and Immunization, said it is preferable for adults under 30 without underlying health conditions to receive another vaccine.
AstraZeneca said its own study did not find a greater risk of blood clots in people who received the vaccine than in the general population.
Scientists are exploring several possible causes for rare cerebral venous thrombosis. One theory suggests that vaccines induce abnormal antibodies in some cases. Other researchers are investigating a possible link with the birth control pill.
But there is no clear evidence yet, and many experts say it is not clear why AstraZeneca’s vaccine will cause problems other vaccines are not used together, targeting similar parts of the virus.
Reporting by Francesco Guarascio, Kate Kelland, Alistair Smout, John Miller, Toby Sterling, Bart Meijer, Anthony Deutsch, Pushkala Aripaka, Stephane Nebehay and Josephine Mason; Written by Nick Macfie; Edited by Kevin Liffey.